Lists of diseases

Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022

Retrieved on: 
Wednesday, October 26, 2022
Bipolar I disorder, Opioid, Alkermes, Webcast, Research, Investor, ALKS, Schizophrenia, Lists of diseases, Nasdaq, Cancer

DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.

Key Points: 
  • DUBLIN, Oct. 26, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m.
  • ET (12:00 p.m. GMT) on Wednesday, Nov. 2, 2022 to discuss the company's third quarter financial results.
  • The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com .
  • Alkermes plcis a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.

FINN Partners and OffScrip Health Join Forces on Multimedia Campaign "Heartbreak in America's Heartland - Crisis in Rural America"

Retrieved on: 
Wednesday, October 26, 2022
People, Health, Communication, Laboratory, Public relations, Smoking, Policy, Restaurant, Patient, Health equity, Twitter, Access, Instagram, Philosophy, Partnership, Technology, Health literacy, Obesity, CEO, Awareness, Climate change, Creativity, Lists of diseases, Depression, Final good, Rural areas in the United States, Empathy, Solution, Pharmaceutical industry, Tech, Health care, Upstate New York, Broadband

WASHINGTON, Oct. 26, 2022 /PRNewswire/ -- FINN Partners, a leading independent, globally integrated marketing and communications firm, announced today that it will join forces with OffScrip Health, one of the leading digital health media platforms focused on patient engagement, health equity, and access to care, for the multimedia campaign "Heartbreak in America's Heartland – Crisis in Rural America." The campaign aims to raise awareness of the many challenges Americans face in rural areas and build advocacy to address the persistent, underlying causes.

Key Points: 
  • WASHINGTON, Oct. 26, 2022 /PRNewswire/ -- FINN Partners , a leading independent, globally integrated marketing and communications firm, announced today that it will join forces with OffScrip Health , one of the leading digital health media platforms focused on patient engagement, health equity, and access to care, for the multimedia campaign "Heartbreak in America's Heartland Crisis in Rural America."
  • The campaign aims to raise awareness of the many challenges Americans face in rural areas and build advocacy to address the persistent, underlying causes.
  • As part of the campaign, OffScrip and FINN Partners will collaborate to enlist a coalition of companies, academic institutions, and nonprofits to participate in the initiative.
  • In addition, FINN provides its clients with access to top-tier agencies worldwide through its membership in the global network PROI.

IM Cannabis's Legacy Strain 'Roma' Voted Israel's Favourite Strain of the Month for August 2022

Retrieved on: 
Wednesday, October 26, 2022
Cannabis, The Company, Nausea, Efficiency, Growth, Lists of diseases, Pharmacy, NASDAQ, Longevity, Quality control, Patient, Trichome, Stock, Company, CSE, Ecosystem, Anxiety, Chronic pain, Migraine, Insomnia, Drug, Pharmaceutical industry, IMC

TORONTO and GLIL YAM, Israel, Oct. 26, 2022 /PRNewswire/ -- IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ: IMCC) (CSE: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada and Germany, is pleased to announce that its legacy strain, Roma, has been voted as the Favourite Strain of the Month in August 2022 by 'Cannabis', one of Israel's leading cannabis blogs for Israeli medical cannabis patients.[1] The Company believes its recent rebranding and restructuring initiatives have significantly contributed to the growing market momentum in Israel.

Key Points: 
  • [1] The Company believes its recent rebranding and restructuring initiatives have significantly contributed to the growing market momentum in Israel.
  • IMC's Roma strain is a high-THC medical cannabis flower that offers a therapeutic continuum and is known for its strength and longevity of effect.
  • The Company's Roma strain has been prescribed in Israel to help relieve chronic pain and migraines, and treat nausea, insomnia, eating disorders, and anxiety.
  • IMC unveiled a series of plans to strengthen its branding and operations in Israel, as stated in its press release dated April 6, 2022.

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

Retrieved on: 
Tuesday, October 25, 2022
Method, News, Asialoglycoprotein receptor, Mode, Spinocerebellar ataxia, U.S. Securities and Exchange Commission, Therapy, Nature Chemical Biology, ATACS, Multiple myeloma, Degenerative disease, Myostatin, NYSE, Neuroscience, Drug development, Hepatocyte, Immunology, Professor, Financial condition report, Result, Security (finance), Lists of diseases, PROTAC, Technology, Cancer, Private Securities Litigation Reform Act, NEW, Conversation, Marketing, Epilepsy, Analysis, Neuropathic pain, Patent, Safety, Tic disorder, Protein, TRPM3, TPD, Proteolysis, FDA, WO, Degradation, Risk, Fine chemical, Pharmaceutical industry, Yale University

Biohaven advances development of its extracellular target degrader platform technology (MoDEs) for therapies across a variety of diseases including neuroscience, immunology and oncology

Key Points: 
  • Biohaven advances development of its extracellular target degrader platform technology (MoDEs) for therapies across a variety of diseases including neuroscience, immunology and oncology
    Through its continued collaboration with Yale University in the laboratory of Professor David Spiegel and Biohaven Labs, Biohaven has made further innovations in this ground-breaking technology with new patent applications covering additional targets and functionality
    In-licensed from Yale University in 2021, the MoDE platform is based on patent applications filed by Yale in 2018 and 2019
    NEW HAVEN, Conn., Oct. 25, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN; "Biohaven") today announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.
  • In 2021, Biohaven entered into a worldwide, exclusive license agreement to develop and commercialize the MoDE platform based on ground-breaking research conducted in the laboratory of Professor David Spiegel at Yale University.
  • Through the novel approach, Professor Spiegel demonstrated the modularity of the MoDE technology by synthesizing bifunctional molecules that induce the degradation of both antibody and pro-inflammatory cytokine proteins.
  • Since entering into the license agreement with Yale in 2021, Yale has filed more than eight additional patent applications covering this technology.

Preclinical biotherapeutics company Abalone Bio and bioinformatics cloud platform provider PipeBio announce collaborative efforts in antibody drug discovery

Retrieved on: 
Tuesday, October 25, 2022
Therapy, Workflow, Lists of diseases, Antibody, Synthetic biology, Research, Cancer, Drug discovery, NGS, CEO, FAST, Membrane protein, Inflammation, Data analysis, Solution, GPCR, Aquaculture

EMERYVILLE, Calif. and HORSENS, Denmark, Oct. 25, 2022 /PRNewswire-PRWeb/ -- Abalone Bio, a preclinical biotherapeutics company and PipeBio, a bioinformatics cloud platform provider, announce their continued collaboration around antibody bioinformatics analysis supporting Abalone Bio's antibody discovery research and development efforts. PipeBio's advanced bioinformatic platform complements Abalone Bio's Functional Antibody Selection Technology (FAST) antibody discovery platform, which aims to find treatments for difficult-to-drug G-protein coupled receptor (GPCR) and other difficult membrane protein targets with disease indications ranging from inflammatory diseases, metabolic diseases, and cancer.

Key Points: 
  • PipeBio's integrated bioinformatics platform supports Abalone Bio's antibody drug discovery efforts to target difficult membrane proteins and enable modulation of previously inaccessible anti-cancer or anti-inflammatory activities.
  • EMERYVILLE, Calif. and HORSENS, Denmark, Oct. 25, 2022 /PRNewswire-PRWeb/ -- Abalone Bio, a preclinical biotherapeutics company and PipeBio, a bioinformatics cloud platform provider, announce their continued collaboration around antibody bioinformatics analysis supporting Abalone Bio's antibody discovery research and development efforts.
  • PipeBio's advanced bioinformatic platform complements Abalone Bio's Functional Antibody Selection Technology (FAST) antibody discovery platform, which aims to find treatments for difficult-to-drug G-protein coupled receptor (GPCR) and other difficult membrane protein targets with disease indications ranging from inflammatory diseases, metabolic diseases, and cancer.
  • Since implementation, the bioinformatics platform from PipeBio has helped Abalone Bio transition into large scale NGS data analysis of antibodies, with single-click analysis pipelines helping Abalone Bio speed up analysis and quickly identify candidate antibody sequences for further development.

Judicial task force studying serious mental illness releases final report, recommendations today

Retrieved on: 
Tuesday, October 25, 2022
Statistics, Substance Abuse, Prevalence, Conference of State Court Administrators, Conference, State, Policy, Health, Mental disorder, Prison, Case management, Mental health, Lists of diseases, Supreme court, SAMHSA, Substance Abuse and Mental Health Services Administration, Medicine, Online gambling, Risk management

WILLIAMSBURG, Va., Oct. 25, 2022 /PRNewswire/ -- After a multi-year investigation, the National Judicial Task Force to Examine State Courts' Response to Mental Illness today is releasing findings and recommendations to assist state courts in responding to the needs of court-involved individuals with serious mental illness.

Key Points: 
  • WILLIAMSBURG, Va., Oct. 25, 2022 /PRNewswire/ -- After a multi-year investigation, the National Judicial Task Force to Examine State Courts' Response to Mental Illness today is releasing findings and recommendations to assist state courts in responding to the needs of court-involved individuals with serious mental illness.
  • Every year, approximately two million arrests are made of people with serious mental illnesses.
  • "The needs of adults, children and families impacted by serious mental illness touches every aspect of the court system," said Lawrence K. Marks, chief administrative judge of New York and task force co-chair.
  • The task force recommendations to state courts include:
    Convene justice and behavioral health system partners to identify opportunities to collaboratively improve responses to individuals with behavioral health disorders.

COUR Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Myasthenia Gravis

Retrieved on: 
Tuesday, October 25, 2022
National Institute, MG, National Institute of Neurological Disorders and Stroke, Yale University, Muscle, Immunodeficiency, Communication, Disease, Assistant, IND, Autoimmune disease, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lists of diseases, Patient, Research, Investigational New Drug, Takeda Pharmaceutical Company, Founder CEO, Nanoparticle, Muscle contraction, Motor neuron, Myasthenia gravis, Technology, Food, Immune system, Immune tolerance, Neurology, CEO, Face, Safety, FDA, Autoimmunity, Stroke, Myasthenia, Program, Vaccine, Pharmaceutical industry

The therapy is designed to treat the underlying autoimmune causes of myasthenia gravis (MG) through antigen-specific tolerance induced by CNP-106.

Key Points: 
  • The therapy is designed to treat the underlying autoimmune causes of myasthenia gravis (MG) through antigen-specific tolerance induced by CNP-106.
  • "CNP-106 has the potential to halt and reverse MG by reprogramming T cells to promote immune tolerance through T regulatory cells.
  • For the first time, we have an opportunity to address the likely seminal trigger which leads to neuromuscular junction damage and dysfunction."
  • "The FDA's acceptance of our IND application in myasthenia gravis represents COUR's fourth IND clearance to date and expands our focus deeper into rare and severe autoimmune diseases," said John J. Puisis, Founder & CEO of COUR.

Boryung, Axiom Space, and Starburst Aerospace Announce Six Winners From The Inaugural 2022 Care In Space Challenge

Retrieved on: 
Tuesday, October 25, 2022
Axiom Space, CFO, Therapy, Program, Entrepreneurship, PVD, Starburst, CEO, Biology, Travel, Vital signs, International Space Station, Aviation, Solution, Astronaut, Neurological disorder, Achievement, MBA, Humanism, Lists of diseases, Executive, Mentorship, MRS, In vivo magnetic resonance spectroscopy, CTO, ATS, Strategy, Development, Government, Diagnosis, Respiration, CIS, Health, Contract, PMP, Research, Ministry of Education (Malaysia), Ecosystem, CPA, Interactive storytelling, Commerce, Axiom Orbital Segment, Terrestrial, COO, Patient, Hospital, Business, UCLA, Face, Scientific research on the International Space Station, Radar, Minneapolis Veterans Affairs Health Care System, Pharmaceutical industry, Video game, Medical device, Axiom

EL SEGUNDO, Calif., Oct. 25, 2022 /PRNewswire/ -- Boryung, an investment and management company, Axiom Space, the world's leading commercial space station company, and Starburst Aerospace, the leading global aerospace and defense startup accelerator and strategic advisory practice, have officially announced the six startup winners of the inaugural Care In Space (CIS) Challenge.

Key Points: 
  • EL SEGUNDO, Calif., Oct. 25, 2022 /PRNewswire/ -- Boryung , an investment and management company, Axiom Space , the world's leading commercial space station company, and Starburst Aerospace , the leading global aerospace and defense startup accelerator and strategic advisory practice, have officially announced the six startup winners of the inaugural Care In Space (CIS) Challenge.
  • Hosted by Boryung in collaboration with Axiom Space and Starburst Aerospace, the CIS Challenge aims to advance the future of space health and the next generation of pharmaceutical, bioscience, and medtech development in space.
  • Space health encompasses all stages of the 'Healthcare Journey' from initial monitoring and diagnosis, to treatment, therapeutics, and continuing care.
  • The 2022 Care In Space Challenge Winners are Advanced TeleSensors, Deep Space Biology, Myelin-H, Nano PharmaSolutions, ViBo Health, and Xtory.

ALMADEN GENOMICS ANNOUNCES LAUNCH OF G.NOME PLATFORM

Retrieved on: 
Tuesday, October 25, 2022
Science, Diagnosis, Genomics, Quality control, Drug development, IBM Research, Research, Multimedia, Lists of diseases, Writing, Nature, Maintenance, Solution, View, Antibiotics, Pharmaceutical industry

DALLAS, Oct. 25, 2022 /PRNewswire/ -- Almaden Genomics has launched g.nome, a cloud-native platform designed to streamline genomic workflows and accelerate genomic discovery.

Key Points: 
  • DALLAS, Oct. 25, 2022 /PRNewswire/ -- Almaden Genomics has launched g.nome, a cloud-native platform designed to streamline genomic workflows and accelerate genomic discovery.
  • "The g.nome platform is a revolutionary approach to bioinformatics that we are launching after an extremely successful customer pilot phase," said Mark Kunitomi, Chief Scientific Officer of Almaden.
  • But, the process is iterative by nature with the writing and maintenance of code significantly slowing time-to-market," added Tricia D'Cruz, Executive Chairperson of Almaden Genomics.
  • Formerly part of IBM Research, Almaden Genomics became a new standalone company under Catalyze Dallas' ownership in 2022.

Valera Health Named in Fast Company's Second Annual List of "Brands That Matter"

Retrieved on: 
Tuesday, October 25, 2022
HEDIS, Physician, Culture, Schizophrenia, Fast Company, B2B, Health, Patient, Depression, Multimedia, SMI, CEO, Brand, Environment, Lists of diseases, Lists of companies, Medicine

BROOKLYN, N.Y., Oct. 25, 2022 /PRNewswire/ -- Valera Health, the leading virtual mental health provider serving high-acuity patients, has been featured on Fast Company's second annual Brands That Matter list. The list honors brands based on relevancy, cultural impact, ingenuity, and business impact.

Key Points: 
  • BROOKLYN, N.Y., Oct. 25, 2022 /PRNewswire/ -- Valera Health, the leading virtual mental health provider serving high-acuity patients, has been featured on Fast Company's second annual Brands That Matter list.
  • "We are honored to be named on Fast Company's list of Brands that Matter," said Dr. Thomas Tsang, CEO of Valera Health.
  • Valera Health's mission is to provide compassionate mental healthcare to those who need it the most, when they need it the most.
  • Valera Health focuses on patients in rural and urban communities and in provider shortage areas, providing culturally intentional care through a diverse, multilingual clinician network.